BVS Stock Overview A medical device company, focuses on developing and commercializing treatments that engage and enhance the body’s natural healing process in the United States and internationally. More details
Rewards Risk Analysis No risks detected for BVS from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Bioventus Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Bioventus Historical stock prices Current Share Price US$10.54 52 Week High US$14.38 52 Week Low US$3.90 Beta 0.84 1 Month Change 10.02% 3 Month Change -10.83% 1 Year Change 139.55% 3 Year Change -14.31% 5 Year Change n/a Change since IPO -45.13%
Recent News & Updates
President notifies of intention to sell stock Jan 15
Bioventus: Amply Rewarded For Recent Progress Jan 05
New minor risk - Profitability Jan 02
Senior VP & CFO notifies of intention to sell stock Dec 24
Second quarter 2024 earnings released: US$0.38 loss per share (vs US$0.059 loss in 2Q 2023) Nov 05
New major risk - Revenue and earnings growth Nov 05 See more updates
President notifies of intention to sell stock Jan 15
Bioventus: Amply Rewarded For Recent Progress Jan 05
New minor risk - Profitability Jan 02
Senior VP & CFO notifies of intention to sell stock Dec 24
Second quarter 2024 earnings released: US$0.38 loss per share (vs US$0.059 loss in 2Q 2023) Nov 05
New major risk - Revenue and earnings growth Nov 05
Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2024 Nov 05
Bioventus Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 29
Forecast to breakeven in 2025 Oct 24
New minor risk - Shareholder dilution Oct 21
New minor risk - Profitability Oct 01
Price target increased by 32% to US$12.33 Sep 27
Forecast breakeven date moved forward to 2024 Sep 18
New minor risk - Shareholder dilution Sep 10
New minor risk - Shareholder dilution Aug 26
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024 Aug 12
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 07
Bioventus Inc. Raises Earnings Guidance for the Full Year 2024 Aug 07
Bioventus Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 May 08
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 08
Bioventus Inc. to Report Q1, 2024 Results on May 07, 2024 May 01
Bioventus Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Senior VP & CFO notifies of intention to sell stock Apr 14
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 14
Bioventus Inc. Provides Earnings Guidance for the Year 2024 Mar 13
New major risk - Revenue and earnings growth Mar 13
Bioventus Inc. to Report Q4, 2023 Results on Mar 12, 2024 Mar 05
Now 21% undervalued Feb 07
Bioventus: Bullish On Path To Profitability Jan 24 Bioventus Inc Announces Executive Changes
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 09
New major risk - Revenue and earnings growth Nov 08
Bioventus Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Interim CEO & Director recently bought US$165k worth of stock Aug 24
Price target increased by 29% to US$4.50 Aug 11
High number of new and inexperienced directors Aug 11
Bioventus Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc. May 25
LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc. May 24 Bioventus Inc. announced delayed 10-Q filing
LifeNet Health, Inc. signed a definitive agreement to acquire Wound Business of Bioventus Inc. May 11
Bioventus Inc. to Report Q1, 2023 Results on May 11, 2023 May 04
Full year 2022 earnings: EPS and revenues miss analyst expectations Apr 02
High number of new and inexperienced directors Feb 16
An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH). Feb 02
An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH). Feb 01
Kirby Mcinerney LLP Announces the Filing of a Securities Class Action on Behalf Bioventus Inc. Investors Jan 24
Bioventus Inc. Appoints John A. Bartholdson to the Board as A Class II Director Jan 10 Bioventus Inc. Announces Impairment of Goodwill for the Three Months Ended October 1, 2022
Bioventus Inc. announced delayed 10-Q filing Nov 17
Price target decreased to US$9.20 Nov 16
High number of new and inexperienced directors Nov 16
Price target decreased to US$9.20 Nov 10
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09
Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2022 Nov 09
Bioventus Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 01
Bioventus: Reiterating Buy Thesis Following Q2 Earnings Sep 08
Bioventus Inc. Announces Resignation of Stavros G. Vizirgianakis as Member of the Board of Directors Sep 02
Price target decreased to US$16.40 Aug 12
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 12
Bioventus Inc. Updates Earnings Guidance for the Full Year 2022 Aug 12
Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M Aug 11
Bioventus Receives FDA 510(k) Clearance for SonaStar Elite Aug 04
Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal Aug 03
Bioventus Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 28
Bioventus Inc. (NasdaqGS:BVS) completes the acquisition of Cartiheal Ltd for $450 million. Jul 13
Bioventus Inc. Announces Executive Changes Jun 30
Bioventus: Strong Value Gap, Insulated Via Leading Market Share Jun 14
Price target decreased to US$19.40 May 17
First quarter 2022 earnings: EPS misses analyst expectations May 10
Bioventus Inc. Reaffirms Earnings Guidance for the Full-Year 2022 May 04
Price target increased to US$21.20 Apr 27
High number of new and inexperienced directors Apr 27
Bioventus Inc. Provides Preliminary Unaudited Earnings Guidance for the First Quarter of 2022 Apr 27
Bioventus Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 26 Bioventus Inc. (NasdaqGS:BVS) acquired unknown remining majority stake in Cartiheal Ltd for approximately $450 million. Apr 06
Bioventus: Thoughts After An Active First Year Mar 29
Price target increased to US$21.20 Mar 21
Price target decreased to US$19.50 Mar 11
Full year 2021 earnings: EPS misses analyst expectations Mar 11
Bioventus Inc. Receives 510(k) Clearance for StimRouter Pain Management Device Mar 03 Bioventus Inc. Appoints Mark Singleton as Senior Vice President and Principal Accounting Officer, Effective March 21, 2022 Shareholder Returns BVS US Medical Equipment US Market 7D -1.3% -0.9% 0.2% 1Y 139.5% 12.5% 22.0%
See full shareholder returns
Return vs Market: BVS exceeded the US Market which returned 22% over the past year.
Price Volatility Is BVS's price volatile compared to industry and market? BVS volatility BVS Average Weekly Movement 7.1% Medical Equipment Industry Average Movement 8.8% Market Average Movement 6.1% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: BVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BVS's weekly volatility (7%) has been stable over the past year.
About the Company Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications.
Show more Bioventus Inc. Fundamentals Summary How do Bioventus's earnings and revenue compare to its market cap? BVS fundamental statistics Market cap US$708.59m Earnings (TTM ) -US$39.48m Revenue (TTM ) US$555.06m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BVS income statement (TTM ) Revenue US$555.06m Cost of Revenue US$183.19m Gross Profit US$371.87m Other Expenses US$411.35m Earnings -US$39.48m
Last Reported Earnings
Sep 28, 2024
Earnings per share (EPS) -0.60 Gross Margin 67.00% Net Profit Margin -7.11% Debt/Equity Ratio 205.3%
How did BVS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 23:26 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/28 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Bioventus Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution William Plovanic Canaccord Genuity Caitlin Cronin Canaccord Genuity Kyle Rose Canaccord Genuity
Show 5 more analysts 
